1 |
ClinicalTrials.gov (NCT04220866) Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002). U.S. National Institutes of Health.
|
2 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
3 |
National Cancer Institute Drug Dictionary (drug name MK1454).
|
4 |
Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
|
5 |
Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
|
6 |
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
|
7 |
National Cancer Institute Drug Dictionary (drug name ML2118).
|
8 |
Clinical pipeline report, company report or official report of F-star Therapeutics.
|
9 |
E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
|
10 |
National Cancer Institute Drug Dictionary (drug name GSK3745417).
|
11 |
National Cancer Institute Drug Dictionary (drug name TAK676).
|
12 |
Clinical pipeline report, company report or official report of Silicon Therapeutics.
|
|
|
|
|
|
|